Fusion Antibodies (LSE:FAB) EPS (Basic) : £-0.08 (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies EPS (Basic)?

Fusion Antibodies's basic earnings per share (Basic EPS) for the six months ended in Sep. 2023 was £-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.08.

Fusion Antibodies's EPS (Diluted) for the six months ended in Sep. 2023 was £-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

Fusion Antibodies's EPS without NRI for the six months ended in Sep. 2023 was £-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.09.

During the past 3 years, the average EPS without NRI Growth Rate was -46.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Fusion Antibodies's highest 3-Year average EPS without NRI Growth Rate was 34.50% per year. The lowest was -46.20% per year. And the median was -15.75% per year.

Fusion Antibodies EPS (Basic) Historical Data

The historical data trend for Fusion Antibodies's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies EPS (Basic) Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EPS (Basic)

Get a 7-Day Free Trial

-0.06

-0.03

-0.11

-0.05

-0.10

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EPS (Basic)	Get a 7-Day Free Trial											-0.02	-0.02	-0.04	-0.06	-0.02

Fusion Antibodies EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Fusion Antibodies's Basic EPS for the fiscal year that ended in Mar. 2023 is calculated as

Basic EPS (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.596	-	0)	/	26.015
	=	-0.10

Fusion Antibodies's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.357	-	0)	/	46.497
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.08

Fusion Antibodies (LSE:FAB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Fusion Antibodies EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022